Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Generalized Pustular Psoriasis (GPP) Market Outlook

Thelansis’s “Generalized Pustular Psoriasis (GPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Pustular Psoriasis (GPP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Generalized Pustular Psoriasis (GPP) Overview

Generalized pustular psoriasis is an uncommon and severe variant of psoriasis, marked by sudden, painful outbreaks of pus-filled blisters covering extensive body areas. It can also bring general symptoms like fever, headaches, extreme fatigue, and skin-burning sensations. Distinguishing it from the more typical plaque psoriasis is essential. Several factors can trigger or worsen generalized pustular psoriasis, including:

1. Infections: Viral or bacterial infections often exacerbate the condition.
2. Medications: Corticosteroids are a significant trigger, but other drugs like ciclosporin, terbinafine, and others have been implicated.
3. Psychological Stress: Stress can lead to deterioration in some individuals.
4. Hypocalcemia: Low calcium levels, either from the disease or other causes like hypoparathyroidism, can activate the condition.
5. Pregnancy: Pregnancy is a recognized risk factor.

In certain populations, genetic mutations in IL36RN have been linked to familial and sporadic cases of generalized pustular psoriasis, with specific mutations varying among populations. Diagnostic laboratory tests include elevated erythrocyte sedimentation rate, C-reactive protein levels, lymphopenia followed by leukocytosis, low plasma albumin, zinc, calcium, and abnormal lipid profiles. The disease may be mistaken for a systemic infection due to fever and elevated inflammatory markers during acute phases, potentially leading to incorrect treatment decisions. Without effective treatment, the acute phase can be life-threatening. Prognosis is generally better when there is a clear trigger, such as pregnancy-related generalized pustular psoriasis. However, cases stemming from acrodermatitis continua of Hallopeau tend to have a worse outlook. Treatment for generalized pustular psoriasis involves various approaches – Conservative Treatment includes – Encouraging adequate fluid and protein intake, Monitoring fluid balance, Addressing any concurrent infections with antibiotics, terminating the pregnancy if maternal life is at risk, and preventing hypothermia. Topical Treatment includes- Applying gentle emollients and Using diluted corticosteroids. Systemic Treatment (in order of preference)- First line- Acitretin (not recommended during pregnancy) at a dose of 1 mg/kg/day, Ciclosporin at 3.5 to 5 mg/kg/day, Methotrexate at 0.2 to 0.4 mg/kg/day. Second line- Infliximab, Adalimumab, Etanercept, Prednisolone (only in specific conditions or complications). Third line – Anakinra.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034